Helsinn, Roche Sue Over Planned Generic Of Nausea Drug

Law360, Washington (October 9, 2015, 7:01 PM EDT) -- Drugmakers Helsinn Healthcare SA and Roche Palo Alto LLC hit two generics makers with a patent suit Thursday over their application for U.S. Food and Drug Administration approval of a version of Helsinn's Aloxi, an intravenous treatment for nausea caused by chemotherapy.

Helsinn and Roche's New Jersey federal complaint alleges that new drug applications filed by Exela Pharma Sciences LLC, Fresenius Kabi USA LLC and related companies infringe five patents for Aloxi, and that their infringement will irreparably harm the plaintiffs absent an injunction.

Switzerland-based Helsinn and California-based Roche claim they received an Aug. 28 letter from Fresenius with information on...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!